Current perspectives on Lifileucel tumor-infiltrating lymphocyte therapy: A paradigm shift in immunotherapy

• Lifileucel is a tumor-infiltrating lymphocyte (TIL) therapy, developed to leverage the patient’s own immune cells for the treatment of advanced metastatic melanoma. • The manufacturing process involves isolating and expanding TILs from a patient’s tumor, enhancing the specificity of the immune response against cancer cells. • Lifileucel has shown promising clinical activity in patients with metastatic melanoma who have progressed on immune checkpoint inhibitors and BRAF/MEK inhibitors, demonstrating significant response rates. • Lifileucel exploits the ability of TILs to recognize a broad array of tumor antigens, offering a comprehensive immune attack compared to therapies that target specific single antigens. Lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, provides renewed hope for individuals with advanced, treatment-resistant malignancies. This is a groundbreaking advancement in cancer immunotherapy. Revolutionizing the way the immune system fights cancer, this state-of-the-art cellular therapy takes advantage of TILs' innate capacity to target tumors. Lifileucel is an innovative medicine that is garnering attention in oncology. It has shown remarkable efficacy in clinical trials, assisting individuals unresponsive to other therapy in sustaining their responses and enhancing their survival rates. This paper provides a comprehensive overview of contemporary perspectives on Lifileucel, including its mechanism of action, clinical results, challenges and potential applicability to a broader spectrum of solid tumors. The Lifileucel concept has initiated a new epoch in personalized cancer therapy. This review offers a forward-looking perspective on the potential advancements and opportunities for establishing Lifileucel and TIL-based therapies as a cornerstone in cancer therapy.